Status:
COMPLETED
Safety and Efficacy of Recombinant Grass Pollen Allergen Cocktail in the Treatment of Allergic Rhinoconjunctivitis
Lead Sponsor:
Allergopharma GmbH & Co. KG
Conditions:
Allergy
Eligibility:
All Genders
18-60 years
Phase:
PHASE3
Brief Summary
The trial is performed to assess efficacy and safety of a recombinant grass Pollen allergen cocktail in allergic rhinoconjunctivitis
Eligibility Criteria
Inclusion
- Positive Skin Prick Test reaction to grass pollen
- Positive RAST result to grass pollen
- Positive Provocation Test result to grass pollen
Exclusion
- Serious chronic diseases
- Other relevant perennial allergies
Key Trial Info
Start Date :
January 1 2004
Trial Type :
INTERVENTIONAL
End Date :
May 1 2008
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00309036
Start Date
January 1 2004
End Date
May 1 2008
Last Update
March 11 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Allergopharma GmbH & Co. KG
Reinbek, Germany, 21465